Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Recommendation of "Buy" from Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) has earned an average rating of "Buy" from the six analysts that are covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $30.83.

A number of research firms have recently commented on TYRA. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, March 31st. Wedbush restated an "outperform" rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, March 28th.

Tyra Biosciences Stock Down 2.7%

TYRA stock traded down $0.28 during midday trading on Monday, reaching $9.98. The company's stock had a trading volume of 212,780 shares, compared to its average volume of 261,228. The business's 50-day simple moving average is $9.60 and its 200-day simple moving average is $13.00. The stock has a market cap of $529.84 million, a PE ratio of -6.20 and a beta of 1.17. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. As a group, equities analysts forecast that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Tyra Biosciences

Several large investors have recently made changes to their positions in the company. Alta Partners Management Company L.P. acquired a new position in Tyra Biosciences during the 4th quarter worth about $56,716,000. Boxer Capital Management LLC acquired a new position in shares of Tyra Biosciences in the fourth quarter valued at approximately $28,185,000. Farallon Capital Management LLC acquired a new position in Tyra Biosciences during the fourth quarter worth $13,914,000. Vestal Point Capital LP acquired a new position in Tyra Biosciences during the fourth quarter worth $13,761,000. Finally, Orbimed Advisors LLC grew its holdings in Tyra Biosciences by 91.3% in the fourth quarter. Orbimed Advisors LLC now owns 1,470,086 shares of the company's stock valued at $20,434,000 after purchasing an additional 701,448 shares during the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.